To date, pilot clinical trials with anti-CTLA-4 antibodies (tremelimumab and ipilimumab) in BC have yielded negative results both in terms of progression-free survival (PFS) and overall survival (OS) [18]. The gene discussed is CTLA4; the disease is breast cancer.